Antipsychotic use in elderly patients with dementia: Efficacy and safety concerns

Mental Health Clinician

Volumn 4, Issue 4, 2014, Pages 170-176

  Marvanova, Marketa ^a,b,c  

^a CHICAGO STATE UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c RUSH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85061767303     PISSN: None     EISSN: 21689709     Source Type: Journal    
DOI: 10.9740/mhc.n204371     Document Type: Article

References (61)

1. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708-14. PubMed PMID: 10784462.
2. Jeste DV, Blazer D, Casey D, et al. ANCP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharm. 2008; 33:957-970.
3. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170-7. DOI: 10.1002/gps.1858. PubMed PMID: 17607801.
4. Spalletta G, Musicco M, Padovani A, Rozzini L, Perri R, Fadda L, et al. Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(11):1026-35. DOI: 10.1097/JGP.0b013e3181d6b68d. PubMed PMID: 20808086.
5. Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimer's Dement, The Alzheimer's Association. 2011;7:532-539.
6. Testad I, Aasland AM, Aarsland D. Prevalence and correlates of disruptive behavior in patients in Norwegian nursing homes. Int J Geriatr Psychiatry. 2007;22(9):916-21. DOI: 10.1002/gps.1766. PubMed PMID: 17323402.
7. Okura T, Langa KM. Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: the Aging, Demographics, and Memory Study (ADAMS). Alzheimer Disease & Associated Disorders. 2011;25(2):116-21. DOI: 10.1097/WAD.0b013e318203f208. PubMed PMID: 21192239; PubMed Central PMCID: PMC3100441.
8. Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. J Am Geriatr Soc. 2010;58(2):330-7. DOI: 10.1111/j.1532-5415.2009.02680.x. PubMed PMID: 20374406.
9. Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Välimäki T, Martikainen J, et al.. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease. Int J Geriatr Psychiatry. 2011;26(5):473-82. DOI: 10.1002/gps.2550. PubMed PMID: 21445998.
10. Chan D-C, Kasper JD, Black BS, Rabins PV. Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis. J Gerontol A Biol Sci Med Sci. 2003;58(6):548-54. PubMed PMID: 12807927.
11. Gilley DW, Bienias JL, Wilson RS, Bennett DA, Beck TL, Evans DA. Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease. Psychol Med. 2004;34(6):1129-35. PubMed PMID: 15554582.
12. Mourik JC, Rosso SM, Niermeijer MF, Duivenvoorden HJ, van Swieten JC, Tibben A. Frontotemporal dementia: behavioral symptoms and caregiver distress. Dement Geriatr Cogn Disord. 2004;18(3-4):299-306. DOI: 10.1159/000080123. PubMed PMID: 15305107.
13. Aarsland D, Brønnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, et al.. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007;78(1):36-42. DOI: 10.1136/jnnp.2005.083113. PubMed PMID: 16820421.
14. Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59(3):473-81. DOI: 10.1111/j.1532-5415.2011.03314.x. PubMed PMID: 21391937.
15. Salzman C, Jeste DV, Meyer RE, Cohen-Mansfield J, Cummings J, Grossberg GT, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69(6):889-98. PubMed PMID: 18494535.
16. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308(19):2020-9. DOI: 10.1001/jama.2012.36918. PubMed PMID: 23168825.
17. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608. DOI: 10.1001/jama.293.5.596. PubMed PMID: 15687315.
18. Savva GM, Zaccai J, Matthews FE, Davidson JE, McKeith I, Brayne C. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry. 2009;194(3):212-9. DOI: 10.1192/bjp.bp.108.049619. PubMed PMID: 19252147.
19. Weiss E, Hummer M, Koller D, Koller D, Ulmer H, Fleischhacker WW. Off-label use of antipsychotic drugs. J Clin Psychopharmacol. 2000;20(6):695-8. PubMed PMID: 11106144.
20. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57(10):968-76. PubMed PMID: 11015815.
21. Kindermann SS, Dolder CR, Bailey A, Katz IR, Jeste DV. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Aging. 2002;19(4):257-76. PubMed PMID: 12038878.
22. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ. 2004;329(7457):75. DOI: 10.1136/bmj.38125.465579.55. PubMed PMID: 15194601.
23. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005;330(7496):874. DOI: 10.1136/bmj.38369.459988.8F. PubMed PMID: 15722369.
24. Schneider LS, Pierre N, Tariot PN, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New Engl J Med. 2006; 355:1525-1538.
25. Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry. 2008;16(7):537-50. DOI: 10.1097/JGP.0b013e318165db77. PubMed PMID: 18591574.
26. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151-7. DOI: 10.1016/S1474-4422(08)70295-3. PubMed PMID: 19138567.
27. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191-210. DOI: 10.1097/01.JGP.0000200589.01396.6d. PubMed PMID: 16505124.
28. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844-54. DOI: 10.1176/appi.ajp.2008.07111779. PubMed PMID: 18519523.
29. Maglione M, Ruelaz Maher A, Hu J, et al., Off-label use of atypical antipsychotics: an update. Comparative Effectiveness Review Number 43. Executive Summary. Rockville, MD: Agency for Healthcare Research and Quality, 2011
30. American Association for Geriatric Psychiatry. AAGP Position Statement=Principles of Care for Patients With Dementia Resulting From Alzheimer Disease. American Association for Geriatric Psychiatry Website:http://www.aagponline.org/index.php?src=news&srctype=detail &category=Position%20Statement&refno=35. Accessed September 5, 2013.
31. APA Work Group on Alzheimer's Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry. 2007; 164(12 Suppl):5-56.
32. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616-31. DOI: 10.1111/j.1532-5415.2012.03923.x. PubMed PMID: 22376048.
33. American Geriatrics Society. Guide to the management of psychotic disorders and neuropsychiatric symptoms of dementia in older adults, April 2011. http://dementia.americangeriatrics.org/GeriPsych_index.php. Accessed November 29, 2013
34. vonMoltke, LL.; Abernethy, DR.; Greenblatt, DJ. Kinetics and dynamics of psychotropic drugs in the elderly. In: Salzman, C., editor. Clinical Geriatric Psychopharmacology. Vol. 4. Philadelphia, PA: Lippincott, Williams and Wilkins; 2005. p. 87-114.
35. Pollock BG. Geriatric psychiatry: Psychopharmacology: General principles. In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock's Comprehensive Textbook of Psychiatry/VIII. Baltimore, MD: Williams & Wilkins; 2005. pp. 3716-3720.
36. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601. PubMed PMID: 14747245.
37. Hasnain M, Fredrickson SK, Vieweg WVR, Pandurangi AK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010;10(3):209-16. DOI: 10.1007/s11892-010-0112-8. PubMed PMID: 20425584.
38. Abilify (aripiprazole), prescribing information. Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan. http://www.otsuka-us.com/Documents/Abilify.PI.pdf. Accessed September 4, 2013.
39. Clozaril (Clozapine), prescribing information. Novartis Pharmaceuticals Corporation. http://pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf. Accessed September 4, 2013.
40. Zyprexa (olanzapine), prescribing information. Lilly USA, LLC, Indianapolis, IN 46285, USA. http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed September 4, 2013.
41. Risperdal (risperidone), prescribing information. Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Titusville, NJ. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf. Accessed September 4, 2013
42. Seroquel (quetiapine), prescribing information. AstraZeneca Pharmaceuticals LP, Wilmington,DE. http://www1.astrazenecaus.com/pi/seroquel.pdf. Accessed September 4, 2013.
43. Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165(16):1882-8. DOI: 10.1001/archinte.165.16.1882. PubMed PMID: 16157833.
44. Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356-63. DOI: 10.1212/01.wnl.0000260060.60870.89. PubMed PMID: 17452579.
45. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13(1):13-24. PubMed PMID: 17242588.
46. Ballard C, Grace J, McKeith lan, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. The Lancet. 1998;351(9108):1032- 1033. DOI: 10.1016/S0140-6736(05)78999-6.
47. Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004;65 Suppl 11:16-22. PubMed PMID: 15264967.
48. Fernandez HH, Wu C-K, Ott BR. Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother. 2003;4(11):2027-37. DOI: 10.1517/14656566.4.11.2027. PubMed PMID: 14596656.
49. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70(1):1-17. DOI: 10.1016/j.schres.2004.01.014. PubMed PMID: 15246458.
50. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 Suppl 1:1-93. PubMed PMID: 15998156.
51. Zheng L, Mack WJ, Dagerman KS, et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. J Clin Psychopharmacol. 2000; 20:695-698.
52. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-43. DOI: 10.1001/jama.294.15.1934. PubMed PMID: 16234500.
53. Trifirò G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?. Pharmacol Res. 2009;59(1):1-12. DOI: 10.1016/j.phrs.2008.09.017. PubMed PMID: 18977443.
54. Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007;164(10):1568-76; quiz 1623. DOI: 10.1176/appi.ajp.2007.06101710. PubMed PMID: 17898349.
55. Rossom RC, Rector TS, Lederle FA, Dysken MW. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?. J Am Geriatr Soc. 2010;58(6):1027-34. DOI: 10.1111/j.1532-5415.2010.02873.x. PubMed PMID: 20487081.
56. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71-9. DOI: 10.1176/appi.ajp.2011.11030347. PubMed PMID: 22193526.
57. Kleijer BC, van Marum RJ, Egberts ACG, Jansen PAF, Knol W, Heerdink ER. Risk of cerebrovascular events in elderly users of antipsychotics. Journal of Psychopharmacology. 2009;23(8):909-14. DOI: 10.1177/0269881108093583. PubMed PMID: 18635700.
58. Herrmann N, Lanctt KL. Do Atypical Antipsychotics Cause Stroke?. CNS Drugs. 2005;19(2):91- 103. DOI: 10.2165/00023210-200519020-00001.
59. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005;66(9):1090-6. PubMed PMID: 16187764.
60. Meeks TW, Jeste DV. Beyond the Black Box: What is The Role for Antipsychotics in Dementia?. Curr Psychiatr. 2008;7(6):50-65. PubMed PMID: 19221607.
61. Ballard C, Lana MM, Theodoulos M, et al. A randomized, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PloS Med. 2008; 1:59:e76.